Two Pharma Giants Went Shopping on the Same Day. Biotech Went Ballistic.
Eli Lilly and Biogen dropped nearly $14 billion in acquisitions on the same day, sending the biotech index soaring 7%. It might be just the beginning of a record-breaking M&A year.
The Day Biotech Broke the Internet
April 2, 2026, started like any other Thursday. It didn't stay that way.
By lunchtime, two of the biggest pharma companies on Earth had each announced multi-billion-dollar acquisitions. On March 31, Eli Lilly grabbed Centessa Pharmaceuticals for up to $7.8 billion. That same day, Biogen swooped in on Apellis Pharmaceuticals for $5.6 billion. The biotech index (XBI) rocketed 2.63% in a single session on April 2, as markets digested the news.
Traders on social media quickly dubbed it "Takeover Tuesday" (yes, the announcements were actually on a Monday, but who's counting). It was one of the most concentrated bursts of biotech dealmaking anyone can remember, and it sent a very clear message: Big Pharma is hungry, and it's not waiting around.
What Lilly Wanted (and What It's Paying)
Eli Lilly's target was Centessa Pharmaceuticals, a clinical-stage company built around a class of drugs called orexin receptor 2 (OX2R) agonists. Think of orexin as your brain's "stay awake" signal. In conditions like narcolepsy and idiopathic hypersomnia (a disorder where people are excessively sleepy no matter how much they sleep), that signal is broken. Centessa's lead drug, cleminorexton, is designed to fix it.
The numbers: Lilly is paying $38.00 per share in cash upfront, plus a contingent value right (CVR) worth up to $9.00 per share if certain FDA approvals come through. That works out to roughly $6.3 billion upfront, with the total potentially reaching $7.8 billion. The upfront price alone represents a 40.5% premium over Centessa's 30-day average trading price.
Cleminorexton is still in Phase 2, which means it hasn't been proven in large-scale trials yet. But early data from the CRYSTAL-1 study, released in November 2025, showed statistically significant improvements in wakefulness and sleepiness scores, with good tolerability. Centessa also has two backup compounds (ORX142 and ORX489) in Phase 1, giving Lilly a whole portfolio of shots on goal.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
The CVR milestones are tied to FDA approvals for narcolepsy type 2 and idiopathic hypersomnia before certain deadlines. It's basically Lilly saying, "We believe in this drug, but we'll pay the full tab once we see the receipts."
Biogen's Billion-Dollar Eye Exam
Meanwhile, Biogen was writing its own check. The target: Apellis Pharmaceuticals, maker of Syfovre, the first FDA-approved treatment for geographic atrophy (GA), a leading cause of blindness in age-related macular degeneration. If you're over 60 and slowly losing your central vision, GA might be the culprit. Until Syfovre came along, there was essentially nothing doctors could do.
Biogen offered $41.00 per share in cash, which represents an eye-popping 86% premium to Apellis' 90-day average stock price and a 35% premium even to its 52-week high. There's also a CVR worth up to $4.00 per share, triggered if Syfovre hits $1.5 billion and $2 billion in annual global sales between 2027 and 2031.
Unlike the Lilly/Centessa deal, Biogen is buying a company with real, current revenue. Syfovre pulled in $587 million in 2025 sales, and Apellis' second product, Empaveli (for rare blood and kidney disorders), brought the combined total to $689 million. Analysts project mid-to-high teens growth through 2028.
The strategic logic goes deeper than ophthalmology. Biogen CEO Christopher Viehbacher pointed to Apellis' nephrology expertise and commercial field force as accelerants for Biogen's own Phase 3 kidney drug, felzartamab. It's like buying a restaurant not just for the menu, but for the kitchen staff and the delivery trucks.
Why Now? The Patent Cliff Is Getting Loud
Two massive deals on the same day doesn't happen by accident. The backdrop here is the patent cliff: a wave of exclusivity expirations that threatens to wipe out tens of billions in annual revenue for large pharma companies over the next four years. When your blockbuster drug goes generic, you need something to replace it. Fast.
Average deal sizes in life sciences jumped 107% in 2025 as companies shifted toward fewer, bigger, more strategic bets. And 2026 is on pace to blow past those numbers. Jefferies projected that M&A volume for deals over $500 million could reach $172 billion this year, up from $111 billion across 32 transactions in 2025.
BMO Capital Markets flagged several pharma giants with massive acquisition capacity still on the sidelines: Novartis ($53 billion), AbbVie ($33.6 billion), Bristol Myers Squibb ($21.9 billion), and Amgen ($18.6 billion). The shopping spree, in other words, may be just getting started.
Takeover Tuesday Was Just the Appetizer
The week following the announcements brought even more deals. Gilead announced an up-to-$5 billion acquisition of Tubulis on April 7, with $3.15 billion upfront. Neurocrine launched a roughly $2.9 billion tender offer for Soleno Therapeutics the day before. Earlier in the quarter, GSK had picked up Rapt Therapeutics for $2.2 billion, and Amgen grabbed Dark Blue Therapeutics for up to $840 million.
Buyers are being selective, though. The pattern is clear: approved products, near-commercial assets, or obvious strategic fits are getting premium offers. Early-stage moonshots without data? Not so much. If your biotech has a Phase 3 readout coming and a clear path to market, congratulations: you might be next on someone's shopping list.
What This Means for the Rest of Us
For investors, the March 31 announcements were a reminder that M&A premiums in biotech can be massive. Apellis shareholders saw a 135% one-day gain. Centessa holders got a 40% premium to recent averages, with more upside if the drugs pan out.
For patients, these deals could accelerate access to important medicines. Lilly's resources could push cleminorexton through late-stage trials faster than Centessa could alone. Biogen's global infrastructure could get Syfovre to more patients worldwide.
And for the broader biotech ecosystem, the message is encouraging. When Big Pharma is willing to spend nearly $14 billion in a single day on innovation, it validates the entire sector's reason for existing. The patent cliff is terrifying for incumbents, but it's a tailwind for the scrappy biotechs building the next generation of medicines.
The biggest question now isn't whether more deals are coming. It's who's next.
Clinical & Regulatory
5 min read
The Pill That Could Kill the Obesity Needle
Eli Lilly just got FDA approval for Foundayo, the first small-molecule obesity pill that you can take anytime, anywhere, no needles required. With $1.7 billion in projected first-year sales and a price that undercuts injectables by 85%, the GLP-1 wars just went oral.
